Skip to main content

Table 4 AEs and ADRs in the safety population in BENEFIT-Korea study

From: Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study

Age (yr) Male Female
AE ADR AE ADR
Young, < 50 26 (7.2) 2 (0.6) 18 (14.5) 3 (2.4)
Middle-aged, 50–69 125 (12.8) 10 (1.0) 83 (16.3) 8 (1.6)
Older, ≥70 84 (15.7) 6 (1.1) 115 (18.1) 7 (1.1)
  1. Values are presented as number (%)
  2. AE adverse event, ADR adverse drug reaction